Works by Kawachi, Hayato

Results: 21

Clinical Characteristics and Prognosis of Patients With Advanced Non-Small-cell Lung Cancer Who Are Ineligible for Clinical Trials.

Published in:

2018

By:

Hayato Kawachi;
Daichi Fujimoto;
Takeshi Morimoto;
Munehiro Ito;
Shunsuke Teraoka;
Yuki Sato;
Kazuma Nagata;
Atsushi Nakagawa;
Kojiro Otsuka;
Keisuke Tomii;
Kawachi, Hayato;
Fujimoto, Daichi;
Morimoto, Takeshi;
Ito, Munehiro;
Teraoka, Shunsuke;
Sato, Yuki;
Nagata, Kazuma;
Nakagawa, Atsushi;
Otsuka, Kojiro;
Tomii, Keisuke

Publication type:

journal article

Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study.

Published in:

European Journal of Clinical Pharmacology, 2023, v. 79, n. 4, p. 503, doi. 10.1007/s00228-023-03452-0

By:

Tanizaki, Satoshi;
Matsumoto, Kinnosuke;
Tamiya, Akihiro;
Taniguchi, Yoshihiko;
Matsuda, Yoshinobu;
Uchida, Junji;
Ueno, Kiyonobu;
Kawachi, Hayato;
Tamiya, Motohiro;
Yanase, Takafumi;
Suzuki, Hidekazu;
Okishio, Kyoichi

Publication type:

Article

Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005).

Published in:

Clinical Lung Cancer, 2024, v. 25, n. 7, p. 643, doi. 10.1016/j.cllc.2024.07.014

By:

Hayato Kawachi;
Motohiro Tamiya;
Yuko Oya;
Go Saito;
Yoshihiko Taniguchi;
Hirotaka Matsumoto;
Yuki Sato;
Taiichiro Otsuki;
Hidekazu Suzuki;
Yasushi Fukuda;
Satoshi Tanaka;
Yoko Tsukita;
Junji Uchida;
Yoshihiko Sakata;
Yuki Nakatani;
Ryota Shibaki;
Daisuke Arai;
Asuka Okada;
Satoshi Hara;
Koichi Takayama

Publication type:

Article

Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.

Published in:

Targeted Oncology, 2024, v. 19, n. 3, p. 411, doi. 10.1007/s11523-024-01045-0

By:

Onoi, Keisuke;
Yamada, Tadaaki;
Morimoto, Kenji;
Kawachi, Hayato;
Tsutsumi, Rei;
Takeda, Takayuki;
Okada, Asuka;
Tamiya, Nobuyo;
Chihara, Yusuke;
Shiotsu, Shinsuke;
Takemura, Yoshizumi;
Yamada, Takahiro;
Hasegawa, Isao;
Katayama, Yuki;
Iwasaku, Masahiro;
Tokuda, Shinsaku;
Takayama, Koichi

Publication type:

Article

Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.

Published in:

Targeted Oncology, 2023, v. 18, n. 6, p. 915, doi. 10.1007/s11523-023-01012-1

By:

Morimoto, Kenji;
Yamada, Tadaaki;
Kawachi, Hayato;
Tamiya, Motohiro;
Negi, Yoshiki;
Goto, Yasuhiro;
Nakao, Akira;
Shiotsu, Shinsuke;
Tanimura, Keiko;
Takeda, Takayuki;
Okada, Asuka;
Harada, Taishi;
Date, Koji;
Chihara, Yusuke;
Hasegawa, Isao;
Tamiya, Nobuyo;
Nishioka, Naoya;
Katayama, Yuki;
Iwasaku, Masahiro;
Tokuda, Shinsaku

Publication type:

Article

Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study.

Published in:

Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1399889

By:

Naoya Nishioka;
Hayato Kawachi;
Tadaaki Yamada;
Motohiro Tamiya;
Yoshiki Negi;
Yasuhiro Goto;
Akira Nakao;
Shinsuke Shiotsu;
Keiko Tanimura;
Takayuki Takeda;
Asuka Okada;
Taishi Harada;
Koji Date;
Yusuke Chihara;
Isao Hasegawa;
Nobuyo Tamiya;
Taiki Masui;
Natsuki Sai;
Masaki Ishida;
Yuki Katayama

Publication type:

Article

Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%.

Published in:

Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1348034

By:

Shota Takei;
Hayato Kawachi;
Tadaaki Yamada;
Motohiro Tamiya;
Yoshiki Negi;
Yasuhiro Goto;
Akira Nakao;
Shinsuke Shiotsu;
Keiko Tanimura;
Takayuki Takeda;
Asuka Okada;
Taishi Harada;
Koji Date;
Yusuke Chihara;
Isao Hasegawa;
Nobuyo Tamiya;
Yuki Katayama;
Naoya Nishioka;
Kenji Morimoto;
Masahiro Iwasaku

Publication type:

Article

Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.

Published in:

Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1303543

By:

Akihiro Yoshimura;
Takayuki Takeda;
Nobutaka Kataoka;
Keiko Tanimura;
Mototaka Fukui;
Yusuke Chihara;
Shota Takei;
Hayato Kawachi;
Kentaro Nakanishi;
Yuta Yamanaka;
Nobuyo Tamiya;
Ryoichi Honda;
Naoko Okura;
Takahiro Yamada;
Kiyoaki Uryu;
Junji Murai;
Shinsuke Shiotsu;
Hiroshige Yoshioka;
Tadaaki Yamada;
Takayasu Kurata

Publication type:

Article

Initial AXL and MCL‐1 inhibition contributes to abolishing lazertinib tolerance in EGFR‐mutant lung cancer cells.

Published in:

Cancer Science, 2024, v. 115, n. 10, p. 3333, doi. 10.1111/cas.16292

By:

Matsui, Yohei;
Yamada, Tadaaki;
Katayama, Yuki;
Hirai, Soichi;
Sawada, Ryo;
Tachibana, Yusuke;
Ishida, Masaki;
Kawachi, Hayato;
Nakamura, Ryota;
Nishioka, Naoya;
Morimoto, Kenji;
Iwasaku, Masahiro;
Horinaka, Mano;
Sakai, Toshiyuki;
Tokuda, Shinsaku;
Takayama, Koichi

Publication type:

Article

Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non‐small cell lung cancer.

Published in:

Cancer Science, 2024, v. 115, n. 5, p. 1656, doi. 10.1111/cas.16130

By:

Ishida, Masaki;
Iwasaku, Masahiro;
Doi, Toshifumi;
Ishikawa, Takeshi;
Tachibana, Yusuke;
Sawada, Ryo;
Ogura, Yuri;
Kawachi, Hayato;
Katayama, Yuki;
Nishioka, Naoya;
Morimoto, Kenji;
Tokuda, Shinsaku;
Yamada, Tadaaki;
Takayama, Koichi

Publication type:

Article

Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients.

Published in:

2019

By:

Hosoya, Kazutaka;
Fujimoto, Daichi;
Kawachi, Hayato;
Sato, Yuki;
Kogo, Mariko;
Nagata, Kazuma;
Nakagawa, Atsushi;
Tachikawa, Ryo;
Hiraoka, Shinya;
Kokubo, Masaki;
Tomii, Keisuke

Publication type:

journal article

Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study).

Published in:

Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231177022

By:

Kawachi, Hayato;
Yamada, Tadaaki;
Yoshimura, Akihiro;
Morimoto, Kenji;
Iwasaku, Masahiro;
Tokuda, Shinsaku;
Kim, Young Hak;
Shimose, Takayuki;
Takayama, Koichi

Publication type:

Article

Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer.

Published in:

JAMA Network Open, 2023, v. 6, n. 7, p. e2322915, doi. 10.1001/jamanetworkopen.2023.22915

By:

Kawachi, Hayato;
Yamada, Tadaaki;
Tamiya, Motohiro;
Negi, Yoshiki;
Goto, Yasuhiro;
Nakao, Akira;
Shiotsu, Shinsuke;
Tanimura, Keiko;
Takeda, Takayuki;
Okada, Asuka;
Harada, Taishi;
Date, Koji;
Chihara, Yusuke;
Hasegawa, Isao;
Tamiya, Nobuyo;
Ishida, Masaki;
Katayama, Yuki;
Morimoto, Kenji;
Iwasaku, Masahiro;
Tokuda, Shinsaku

Publication type:

Article

First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.

Published in:

Cancers, 2023, v. 15, n. 20, p. 4988, doi. 10.3390/cancers15204988

By:

Tanimura, Keiko;
Takeda, Takayuki;
Kataoka, Nobutaka;
Yoshimura, Akihiro;
Nakanishi, Kentaro;
Yamanaka, Yuta;
Yoshioka, Hiroshige;
Honda, Ryoichi;
Uryu, Kiyoaki;
Fukui, Mototaka;
Chihara, Yusuke;
Takei, Shota;
Kawachi, Hayato;
Yamada, Tadaaki;
Tamiya, Nobuyo;
Okura, Naoko;
Yamada, Takahiro;
Murai, Junji;
Shiotsu, Shinsuke;
Kurata, Takayasu

Publication type:

Article

Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non‐Small‐Cell Lung Cancer.

Published in:

Oncologist, 2024, v. 29, n. 5, p. e681, doi. 10.1093/oncolo/oyae001

By:

Katayama, Yuki;
Yamada, Tadaaki;
Sawada, Ryo;
Kawachi, Hayato;
Morimoto, Kenji;
Watanabe, Satoshi;
Watanabe, Kageaki;
Takeda, Takayuki;
Chihara, Yusuke;
Shiotsu, Shinsuke;
Hibino, Makoto;
Harada, Taishi;
Nishioka, Naoya;
Iwasaku, Masahiro;
Tokuda, Shinsaku;
Takayama, Koichi

Publication type:

Article

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.

Published in:

NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00350-7

By:

Katayama, Yuki;
Yamada, Tadaaki;
Tanimura, Keiko;
Tokuda, Shinsaku;
Morimoto, Kenji;
Hirai, Soichi;
Matsui, Yohei;
Nakamura, Ryota;
Ishida, Masaki;
Kawachi, Hayato;
Yoneda, Kazue;
Hosoya, Kazutaka;
Tsuji, Takahiro;
Ozasa, Hiroaki;
Yoshimura, Akihiro;
Iwasaku, Masahiro;
Kim, Young Hak;
Horinaka, Mano;
Sakai, Toshiyuki;
Utsumi, Takahiro

Publication type:

Article

Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.

Published in:

Investigational New Drugs, 2024, v. 42, n. 5, p. 538, doi. 10.1007/s10637-024-01467-7

By:

Tachibana, Yusuke;
Morimoto, Kenji;
Yamada, Tadaaki;
Kawachi, Hayato;
Tamiya, Motohiro;
Negi, Yoshiki;
Goto, Yasuhiro;
Nakao, Akira;
Shiotsu, Shinsuke;
Tanimura, Keiko;
Takeda, Takayuki;
Okada, Asuka;
Harada, Taishi;
Date, Koji;
Chihara, Yusuke;
Hasegawa, Isao;
Tamiya, Nobuyo;
Katayama, Yuki;
Nishioka, Naoya;
Iwasaku, Masahiro

Publication type:

Article

Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 634, doi. 10.1007/s10637-022-01214-w

By:

Kawachi, Hayato;
Tamiya, Motohiro;
Matsumoto, Kinnosuke;
Tamiya, Akihiro;
Yanase, Takafumi;
Tanizaki, Satoshi;
Kumagai, Toru

Publication type:

Article

Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab.

Published in:

Investigational New Drugs, 2021, v. 39, n. 1, p. 232, doi. 10.1007/s10637-020-00966-7

By:

Tamiya, Motohiro;
Kunimasa, Kei;
Nishino, Kazumi;
Matsumoto, Shingo;
Kawachi, Hayato;
Kuno, Kika;
Inoue, Takako;
Kuhara, Hanako;
Imamura, Fumio;
Goto, Koichi;
Kumagai, Toru

Publication type:

Article

Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.

Published in:

Investigational New Drugs, 2020, v. 38, n. 1, p. 211, doi. 10.1007/s10637-019-00882-5

By:

Kawachi, Hayato;
Tamiya, Motohiro;
Tamiya, Akihiro;
Ishii, Seigo;
Hirano, Katsuya;
Matsumoto, Hirotaka;
Fukuda, Yasushi;
Yokoyama, Toshihide;
Kominami, Ryota;
Fujimoto, Daichi;
Hosoya, Kazutaka;
Suzuki, Hidekazu;
Hirashima, Tomonori;
Kanazu, Masaki;
Sawa, Nobuhiko;
Uchida, Junji;
Morita, Mitsunori;
Makio, Takeshi;
Hara, Satoshi;
Kumagai, Toru

Publication type:

Article

Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab.

Published in:

Investigational New Drugs, 2019, v. 37, n. 6, p. 1257, doi. 10.1007/s10637-019-00770-y

By:

Kawachi, Hayato;
Fujimoto, Daichi;
Morimoto, Takeshi;
Hosoya, Kazutaka;
Sato, Yuki;
Kogo, Mariko;
Nagata, Kazuma;
Nakagawa, Atsushi;
Tachikawa, Ryo;
Tomii, Keisuke

Publication type:

Article